Get the Stockscreener App
19.75
0.18%
0.035
Syndax Pharmaceuticals Inc stock is traded at $19.75, with a volume of 1.05M.
It is up +0.18% in the last 24 hours and up +28.63% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$19.71
Open:
$19.55
24h Volume:
1.05M
Relative Volume:
0.40
Market Cap:
$1.72B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-6.6706
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-0.63%
1M Performance:
+28.63%
6M Performance:
+80.16%
1Y Performance:
+16.70%
1-Day Range:
$19.31
$20.03
1-Week Range:
$18.36
$20.20
52-Week Range:
$8.58
$20.20
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.75 | 1.71B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsQuarterly Portfolio Report & Verified Momentum Watchlists - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock a buy during volatile marketsCPI Data & Safe Capital Growth Tips - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals (Nasdaq: SNDX) issues inducement stock options for 15,500 shares to new hire - Stock Titan
Is Syndax Pharmaceuticals Inc. (1T3) stock positioned for digital growth eraWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Syndax Pharmaceuticals (SNDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Syndax Pharmaceuticals Inc a good long term investmentEarnings Growth Projections & Maximize Returns With Insights - earlytimes.in
What insider purchases suggest about Syndax Pharmaceuticals Inc. (1T3) stockMarket Movement Recap & High Accuracy Swing Entry Alerts - Newser
Why Syndax Pharmaceuticals Inc. (1T3) stock could rally stronglyJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Can Syndax Pharmaceuticals Inc. (1T3) stock reach $200 price targetCEO Change & High Return Trade Opportunity Guides - Newser
CFO Goldan Gifts 1,224 Of Syndax Pharmaceuticals Inc [SNDX] - TradingView
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference - The Manila Times
Syndax Pharmaceuticals (Nasdaq: SNDX) to present fireside chat at 8th Annual Evercore Healthcare Conference - Stock Titan
Geode Capital Management LLC Has $19.20 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Analyst Calls & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Syndax Pharmaceuticals, Inc. $SNDX is Aisling Capital Management LP's 3rd Largest Position - MarketBeat
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha
Syndax Pharmaceuticals, Inc. $SNDX Stock Position Boosted by Franklin Resources Inc. - MarketBeat
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating - MSN
Syndax Pharmaceuticals Grows Revenue As Wall Street Stays Bullish - Finimize
10 Most Promising Stocks with Huge Upside Potential - Insider Monkey
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Rhenman & Partners Asset Management AB - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 10.9% Higher After Analyst Upgrade - MarketBeat
Syndax Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating - MSN
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $35.00 at Barclays - MarketBeat
Barclays Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation - Nasdaq
SNDX Analyst Update: Barclays Raises Price Target to $35 | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals stock hits 52-week high at 18.14 USD By Investing.com - Investing.com Canada
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up - simplywall.st
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 29% But Growth Is Lacking - 富途牛牛
Mizuho Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year HighHere's Why - MarketBeat
Is Syndax Pharmaceuticals Inc. stock poised for growthWeekly Trend Summary & Fast Entry High Yield Stock Tips - newser.com
How Syndax Pharmaceuticals Inc. (1T3) stock compares with tech leadersWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Syndax at Jefferies: Strategic Growth in Hematologic Therapies By Investing.com - Investing.com Canada
Is Syndax Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
How Syndax Pharmaceuticals Inc. (1T3) stock gains from tech spendingJuly 2025 Recap & Daily Price Action Insights - newser.com
Why (SNDX) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
How Syndax Pharmaceuticals Inc. (1T3) stock trades under stagflationJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Is Syndax Pharmaceuticals Inc. stock reversal real or fakeMarket Activity Recap & Daily Technical Forecast Reports - newser.com
How Syndax Pharmaceuticals Inc. stock performs in stagflation2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
A Look at Syndax Pharmaceuticals's Valuation After Revuforj’s FDA Approval and NCCN Inclusion - sahmcapital.com
Published on: 2025-11-19 00:07:46 - newser.com
Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib - MSN
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):